Treatment of Sleep, Motor and Sensory Symptoms with the Orexin Antagonist Suvorexant in Adults with Idiopathic Restless Legs Syndrome: A Randomized Double-Blind Crossover Proof-of-Concept Study

ConclusionsOur results provide the first proof of evidence of the therapeutic efficacy of DORAs in improving sleep and sensory and motor symptoms in RLS. Given orexin ’s role in pain and sensory processing, potential mechanisms of action are discussed.Classification of EvidenceThe study provides class II evidence supporting the therapeutic efficacy of suvorexant in patients with RLS with sleep disturbance. Trial Registration: EudraCT#: 2017-004580-12.

http://link.springer.com/10.1007/s40263-023-01055-y

Source: CNS Drugs - January 21, 2024 Category: Neurology Source Type: research